What question did this study set out to answer?

April 17, 2026Acta Dermato VenereologicaOpen Access

Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)

View Full Paper

Ask AI

Bookmark

Authors

EPElena Pezzolo RMRossi Mariateresa RSRaul Armando Luyo Saboya

Discussion

Member takes

Overview

This retrospective study evaluates abrocitinib's effectiveness and safety for treating atopic dermatitis in adults, indicating promising results over one year.

Key Points

To assess the efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adults.
Retrospective data collection from 187 adult patients in Italian dermatology centres.
Patients received abrocitinib at doses of 100 mg or 200 mg over a year.
Evaluation of clinical outcomes using Investigator Global Assessment and Eczema Area and Severity Index.
52% of patients achieved Investigator Global Assessment 0/1 at week 8, increasing to 88% at week 52.
EASI-90 response reached 79.6%, and Peak Pruritus-Numerical Rating Scale 0/1 was achieved by 73.5%.
18% met minimal disease activity at week 8, rising to 66% at week 52.
Safety profile showed mostly mild adverse events, especially with the 100 mg dose.

Cite This Study

Pezzolo et al. (2026) studied this question.

synapsesocial.com/papers/69e1cdc45cdc762e9d8570bc https://doi.org/10.2340/actadv.v106.adv-2025-0193

View Full Paper

Ask AI

Bookmark

April 17, 2026Acta Dermato VenereologicaOpen Access

Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)

View Full Paper

Ask AI

Bookmark

Authors

EPElena Pezzolo RMRossi Mariateresa RSRaul Armando Luyo Saboya

Discussion

Member takes

Overview

This retrospective study evaluates abrocitinib's effectiveness and safety for treating atopic dermatitis in adults, indicating promising results over one year.

Key Points

To assess the efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adults.
Retrospective data collection from 187 adult patients in Italian dermatology centres.
Patients received abrocitinib at doses of 100 mg or 200 mg over a year.
Evaluation of clinical outcomes using Investigator Global Assessment and Eczema Area and Severity Index.
52% of patients achieved Investigator Global Assessment 0/1 at week 8, increasing to 88% at week 52.
EASI-90 response reached 79.6%, and Peak Pruritus-Numerical Rating Scale 0/1 was achieved by 73.5%.
18% met minimal disease activity at week 8, rising to 66% at week 52.
Safety profile showed mostly mild adverse events, especially with the 100 mg dose.

Cite This Study

Pezzolo et al. (2026) studied this question.

synapsesocial.com/papers/69e1cdc45cdc762e9d8570bc https://doi.org/10.2340/actadv.v106.adv-2025-0193

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark